Literature DB >> 26045807

P16 and Ki-67 expression improves the diagnostic accuracy of cervical lesions but not predict persistent high risk human papillomavirus infection with CIN1.

Pingping Zhong1, Jifeng Li2, Yiqun Gu1, Yu Liu3, Aichun Wang1, Yunfei Sun1, Lijuan Lu1.   

Abstract

OBJECTIVE: To determine the association between the expression of p16 and Ki-67 and cervical lesions, and to evaluate the role of p16 and Ki-67 as prognostic markers for persistent high risk human papillomavirus (hr-HPV) infection.
METHODS: Totally 1,154 cases of cervical biopsies were enrolled, 331 cases with negative for dysplasia (NEG), 462 with cervical intraepithelial neoplasia 1 (CIN1), 176 with CIN2, 163 with CIN3 and 22 with cervical squamous cell carcinoma (SCC). Furthermore, 283 women with CIN1 were recruited into 12-month follow-up, and HPV specific gene detection by polymerase chain reaction was used to detect hr-HPV of cervical secretions at 6-month-interval for 12-month follow-up period. 40 women were infected with persistent hr-HPV, 182 with transient infection and 61 unfected with hr-HPV. The expression of p16 and Ki-67 were evaluated by immunohistochemical method. The immunostaining results of p16 and Ki-67 were classified into four categories: negative, 1+, 2+ and 3+.
RESULTS: There was significant increase in the expression of p16 (P<0.001) and Ki-67 (P<0.001) from NEG to SCC. The expression of Ki-67 (P<0.001) but not p16 (P=0.254) significantly increased in CIN2, CIN3. Ratio of p16 (P=0.215) and Ki-67 (P=0.495) positivity were not correlated with persistent hr-HPV infection.
CONCLUSION: P16 and Ki-67 can improve the diagnostic accuracy of cervical lesions but can not predict persistent hr-HPV infection with CIN1.

Entities:  

Keywords:  Cervical intraepithelial neoplasia (CIN); Ki-67; human papillomavirus (HPV); immunohistochemistry; p16

Mesh:

Substances:

Year:  2015        PMID: 26045807      PMCID: PMC4440116     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

1.  Histological 'progression' from low (LSIL) to high (HSIL) squamous intraepithelial lesion is an uncommon event and an indication for quality assurance review.

Authors:  Eleanor Y Chen; Ann Tran; Caroline J Raho; Chandler M Birch; Christopher P Crum; Michelle S Hirsch
Journal:  Mod Pathol       Date:  2010-05-14       Impact factor: 7.842

2.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

3.  Human papillomavirus genotyping by oligonucleotide microarray and p16 expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women.

Authors:  Zhen-Hua Lin; Xiong-Hu Shen; Zhe Jin; Youngsik Kim; Eungseok Lee; Hankyeom Kim; Insun Kim
Journal:  Pathol Int       Date:  2005-08       Impact factor: 2.534

4.  The expressions of the Rb pathway in cervical intraepithelial neoplasia; predictive and prognostic significance.

Authors:  Eun Ji Nam; Jae Wook Kim; Sang Wun Kim; Young Tae Kim; Jae Hoon Kim; Bo Sung Yoon; Nam Hoon Cho; Sunghoon Kim
Journal:  Gynecol Oncol       Date:  2006-10-13       Impact factor: 5.482

5.  p16(INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome.

Authors:  M Branca; M Ciotti; D Santini; L Di Bonito; C Giorgi; A Benedetto; P Paba; C Favalli; S Costa; A Agarossi; M Alderisio; K Syrjänen
Journal:  Int J Gynecol Pathol       Date:  2004-10       Impact factor: 2.762

6.  Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts.

Authors:  Kari Syrjänen; Irena Shabalova; Paulo Naud; Vladimir Kozachenko; Sophie Derchain; Sergej Zakharchenko; Cecilia Roteli-Martins; Raisa Nerovjna; Adhemar Longatto-Filho; Ludmila Kljukina; Silvio Tatti; Marina Branovskaja; Luciano Serpa Hammes; Margherita Branca; Valerija Grunjberga; Mojca Erzen; Luis Otavio Sarian; Anna Juschenko; Silvano Costa; Jurij Podistov; Stina Syrjänen
Journal:  Int J Gynecol Cancer       Date:  2009-07       Impact factor: 3.437

7.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia.

Authors:  G Y Ho; R D Burk; S Klein; A S Kadish; C J Chang; P Palan; J Basu; R Tachezy; R Lewis; S Romney
Journal:  J Natl Cancer Inst       Date:  1995-09-20       Impact factor: 13.506

Review 8.  Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer.

Authors:  Maria Lina Tornesello; Luigi Buonaguro; Paolo Giorgi-Rossi; Franco M Buonaguro
Journal:  Biomed Res Int       Date:  2013-12-09       Impact factor: 3.411

9.  Characterization of p16 and E6 HPV-related proteins in uterine cervix high-grade lesions of patients treated by conization with large loop excision.

Authors:  Maria Teresa Roncaglia; José Humberto T G Fregnani; Maricy Tacla; Silvana Gisele Pegorin DE Campos; Hélio Hehl Caiaffa; Alexandre Ab'saber; Eduardo Vieira DA Motta; Venâncio Avancini Ferreira Alves; Edmund C Baracat; Adhemar Longatto Filho
Journal:  Oncol Lett       Date:  2013-05-20       Impact factor: 2.967

10.  Detection and pathological value of papillomavirus DNA and p16INK4A and p53 protein expression in cervical intraepithelial neoplasia.

Authors:  Jingbo Wu; Xiao-Jing Li; Wei Zhu; Xiu-Ping Liu
Journal:  Oncol Lett       Date:  2014-01-14       Impact factor: 2.967

View more
  7 in total

1.  On-chip immunofluorescence analysis of single cervical cells using an electroactive microwell array with barrier for cervical screening.

Authors:  Makoto Takeuchi; Kazunori Nagasaka; Mina Yoshida; Yoshiko Kawata; Yuko Miyagawa; Saori Tago; Haruko Hiraike; Osamu Wada-Hiraike; Katsutoshi Oda; Yutaka Osuga; Tomoyuki Fujii; Takuya Ayabe; Soo Hyeon Kim; Teruo Fujii
Journal:  Biomicrofluidics       Date:  2019-07-30       Impact factor: 2.800

2.  WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7.

Authors:  Katsuyoshi Kumagai; Masakatsu Takanashi; Shin-Ichiro Ohno; Yuichirou Harada; Koji Fujita; Keiki Oikawa; Katsuko Sudo; Shun-Ichi Ikeda; Hirotaka Nishi; Kosuke Oikawa; Masahiko Kuroda
Journal:  Oncogene       Date:  2021-05-04       Impact factor: 9.867

3.  p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China.

Authors:  Lu-Lu Yu; Hui-Qin Guo; Xiao-Qin Lei; Yu Qin; Ze-Ni Wu; Le-Ni Kang; Xun Zhang; You-Lin Qiao; Wen Chen
Journal:  Oncotarget       Date:  2016-10-04

4.  An interaction network driven approach for identifying biomarkers for progressing cervical intraepithelial neoplasia.

Authors:  Shikha Suman; Ashutosh Mishra
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

5.  Combining HPV DNA load with p16/Ki-67 staining to detect cervical precancerous lesions and predict the progression of CIN1-2 lesions.

Authors:  Yuejie Li; Jie Liu; Li Gong; Xingwang Sun; Wenbo Long
Journal:  Virol J       Date:  2019-10-16       Impact factor: 4.099

6.  Role of p16 testing in cervical cancer screening among HIV-infected women.

Authors:  Christine J McGrath; Rochelle Garcia; Trong T Trinh; Barbra A Richardson; Grace C John-Stewart; Evans Nyongesa-Malava; Nelly R Mugo; Emily H Glynn; Samah R Sakr; Hugo De Vuyst; Michael H Chung
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

7.  Introduction of p16INK4a as a surrogate biomarker for HPV in women with invasive cervical cancer in Sudan.

Authors:  Hina Sarwath; Devendra Bansal; Nazik Elmalaika Husain; Mahmoud Mohamed; Ali A Sultan; Shahinaz Bedri
Journal:  Infect Agent Cancer       Date:  2017-09-30       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.